The weight loss pen tirzepatide 60mg: what's inside, and what it means for you

Each Mounjaro KwikPen contains four weekly doses at one strength; the six licensed UK strengths run from 2.5mg to 15mg, there is no 60mg formulation.
The 2.5mg starting dose exists to settle tolerability, not to produce weight loss; your prescriber titrates upward over weeks based on your response.
Queries for a 60mg pen are a known red flag: sellers advertising unlicensed or non-existent dose combinations should be reported to the MHRA via Yellow Card at yellowcard.mhra.gov.uk.
Trial evidence for tirzepatide comes from SURMOUNT-1, which randomised 2,539 adults and reported approximately 20–21% average body-weight reduction at the 15mg dose over 72 weeks.

There is no 60mg tirzepatide weight loss pen. The figure circulates online, but no such dose exists in the UK or anywhere else. Tirzepatide is licensed in six strengths — 2.5mg, 5mg, 7.5mg, 10mg, 12.5mg and 15mg — and each Mounjaro KwikPen holds four of your weekly doses at a single strength. Understanding what the pen actually contains matters, because confusion about dosing can lead people toward unverified sources selling products that do not exist. These are prescription-only medicines that require a clinical assessment before any prescriber can approve them, a fact that protects you as much as it regulates the market.

Starting from £29.99/mo

Free 2-minute consultation · Reviewed same day

Start journey
The nume Promise

Order by 12pm.

At your door the next working day.
Free, tracked, plain packaging.

Guaranteed on approved orders

Where are you starting from?

BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.

Check your BMI.

Ten seconds. Private — nothing is stored or shared.

80 kg
170 cm

Your result updates live in the card alongside.

Your result

Your BMI is

which is in the healthy weight range

Start journey

BMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.

Treatment options

Weight loss treatments

The problem

Most weight loss services treat you like a transaction, a checkout, a courier, and you're on your own.

Algorithm approvalsNo real clinicianGeneric dosingHidden feesSlow deliverySilence after checkout

The nume way

We built the opposite: one clinician who knows you, guaranteed care at every step.

24 hrs

clinician review. Free next working day delivery.

How it works

From consultation to your door, properly.

Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.

Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.

Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.

Why the 60mg figure appears, what the pen really contains, and what to do with this information

The myth: there is a 60mg tirzepatide pen available to buy

This is the single biggest misconception built around this search query, and it is worth tackling head-on. No medicines regulator (not the MHRA, not the EMA, not the FDA) has approved a 60mg tirzepatide pen for any indication. The licensed UK product, Mounjaro, comes in six fixed strengths. The highest is 15mg once weekly. The 60mg figure may arise from people misreading the pen's total content (a single KwikPen holds four doses, so a 15mg pen contains 60mg of tirzepatide in total across those four injections), but that total volume is never administered at once, and it is not a licensed dose.

This distinction is not a technicality. Sellers who advertise a "60mg weight loss pen" are either describing their product incorrectly or selling something that falls outside the licensed supply chain. Both situations carry real risk. The MHRA has seized approximately 20 million doses (around £45 million street value) of illegally traded weight-loss medicines, including counterfeit tirzepatide pens raided from an illicit manufacturing site in Northampton in October 2025. If you encounter any seller offering a 60mg tirzepatide pen, that is a clear prompt to walk away and report the listing at yellowcard.mhra.gov.uk.

What the tirzepatide pen actually contains, and how the dose schedule works

The Mounjaro KwikPen is a pre-filled, disposable device with four weekly doses pre-loaded at a single strength. A 2.5mg pen delivers 2.5mg per injection across four weeks; a 15mg pen delivers 15mg per injection. Each pen has its own colour-coded label precisely to prevent mix-ups. You use the pen once a week, on the same day each week if possible, and replace it with a fresh one the following month.

Treatment starts at 2.5mg. That first dose exists to let your digestive system adjust, nausea and mild GI discomfort are most likely in the early weeks, and starting low reduces how severe those effects tend to be. Your prescriber typically reviews your response after four weeks and decides whether to move you up to 5mg, and so on through the schedule. The titration is clinical, not automatic. For a full walk-through of how the pen is used in practice, the step-by-step injection guide covers technique, rotation sites and storage in detail.

Storage is straightforward day-to-day: keep the pen refrigerated between 2°C and 8°C. There is a limited window during which it can be kept at room temperature, but the exact duration is specified in the Patient Information Leaflet rather than here, the leaflet is the right document for that, and it comes with every pen. A pack of alcohol swabs is worth having nearby; cleaning the injection site before each use is standard practice.

Eligibility for tirzepatide, and who makes the prescribing decision

The licensed criteria for tirzepatide in the UK (set out in the SmPC and summarised by the NHS medicines page for tirzepatide) cover adults with a BMI of 30 or above, or those with a BMI from 27 upward if at least one weight-related condition is present (such as high blood pressure, type 2 diabetes, high cholesterol or obstructive sleep apnoea). Lower thresholds apply for some ethnic backgrounds under UK clinical guidance. A BMI figure alone does not guarantee approval; the prescriber considers the whole clinical picture, including current medicines, past history and whether anything in your background contraindicates treatment.

Tirzepatide is not licensed for anyone under 18, and it is not recommended during pregnancy, breastfeeding or while actively trying to conceive. If you take an oral contraceptive pill, your prescriber will explain the guidance around adding a non-oral method for the first four weeks of treatment and for four weeks after each dose increase, because absorption of the pill can be affected.

At nume, a GPhC-registered Independent Prescriber reads your consultation (a real clinician, not a decision algorithm) and responds the same day. If you order by midday on a working day and your prescription is approved, the pen is dispatched that afternoon and arrives with DPD the next working day in plain, unbranded packaging. If you would like to understand more about how the weight loss pen tirzepatide works, including its mechanism and what to expect from treatment, that page covers the detail clearly. For an overview of what private tirzepatide treatment costs, including what a legitimate price should cover, that page sets out the full picture honestly. If you are ready to see whether you qualify, the starting point is a free consultation with our prescribers.

Looking to start your weight loss journey?
Take a quick eligibility quiz to explore your options and see how we can support you.
Start free consultation

The people

Meet the team.

Mahommed Zunaid Ayub Patel

Superintendent Pharmacist (GPhC No. 2217101)

Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.

Mostafa Damghani

Clinical Lead (GPhC No. 2231744)

Sets our clinical standards and checks everything we publish against current MHRA guidance.

Shelan Salih

Independent Prescriber (GPhC No. 2084501)

Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.

Rehenaaz Uddin

Independent Prescriber (GPhC No. 2083426)

Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.

Frequently asked questions